Inflammatory bowel diseases · 2026
Efficacy and safety of ulcerative colitis therapies do not differ by age: A post hoc analysis of randomized controlled trials.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wong Emily C L, Marshall John K, Ma Christopher, Jairath Vipul, Reinisch Walter, Narula Neeraj
Аннотация
BACKGROUND: Older adults with ulcerative colitis (UC) are often undertreated with advanced therapies due to safety concerns. We evaluated whether outcomes differ by age in randomized trials.
METHODS: Post hoc analysis of 2841 participants from 13 UC induction trials of biologics and JAK inhibitors compared efficacy (patient-reported outcomes 2 response/remission, clinical remission, endoscopic improvement) and safety between patients ≥60 years of age vs <60 years of age.
RESULTS: Efficacy and safety outcomes were similar across age groups, with minor therapy-specific variation. Hospitalization was numerically higher in older adults.
CONCLUSIONS: Advanced therapies show comparable efficacy and safety in UC regardless of age.
METHODS: Post hoc analysis of 2841 participants from 13 UC induction trials of biologics and JAK inhibitors compared efficacy (patient-reported outcomes 2 response/remission, clinical remission, endoscopic improvement) and safety between patients ≥60 years of age vs <60 years of age.
RESULTS: Efficacy and safety outcomes were similar across age groups, with minor therapy-specific variation. Hospitalization was numerically higher in older adults.
CONCLUSIONS: Advanced therapies show comparable efficacy and safety in UC regardless of age.